Application | Comment | Organism |
---|---|---|
medicine | development of an NQO1-targeted radiolabeled agent to establish an internal radiation therapy that amplifies the therapeutic effects when combined with external radiation therapy. The uptake of [125I]-marked compound 3-([[4-iodophenyl]thio]methyl)-5-methoxy-1,2-dimethyl-1H-indole-4,7-dione is specific and is dependent on the expression of NQO1. In NQO1-expressing tumor cells, over 85% of the initial radioactivity of [125I]-marked 3-([[4-iodophenyl]thio]methyl)-5-methoxy-1,2-dimethyl-1H-indole-4,7-dione is observed as an intact form at 1 h after incubation | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
3-([[4-Iodophenyl]thio]methyl)-5-methoxy-1,2-dimethyl-1H-indole-4,7-dione | compound based on the selective binding of indolequinone analogs to the active site of NQO1 by the stacking effect. [125]I-marked compound can be used as an internal radiation agent for the treatment of cancer | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | P15559 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
HT-29 cell | - |
Homo sapiens | - |